Literature DB >> 23057037

Oral bisphosphonates: early endosseous dental implant success and crestal bone changes. A retrospective study.

Sayma Memon1, Robin L Weltman, James A Katancik.   

Abstract

PURPOSE: The purpose of this retrospective chart-review study was to compare the early success rate and the crestal bone changes of dental implants in patients taking oral bisphosphonates at the time of implant placement to those of patients who had never taken bisphosphonates.
MATERIALS AND METHODS: A retrospective chart review of 100 women (153 implants) taking oral bisphosphonates at the time of implant placement (test group) and 100 women (132 implants) who had never taken bisphosphonates (control group) was performed to examine overall implant success at the time of stage-two surgery. Radiographic images, which were available for 73 patients in each group and were taken at the time of implant placement and at stage-two surgery, were analyzed to assess and compare crestal bone changes around the implants.
RESULTS: There was no significant difference between groups in the success rates of dental implants at stage-two surgery (test 93.5%, control 95.5%). The change in crestal bone height was statistically significant from the time of placement to stage-two surgery within both groups but was not significantly different between groups (means ± standard deviations: test, 0.66 ± 0.70 mm; control: 0.80 ± 0.65 mm).
CONCLUSIONS: In this study, the use of oral bisphosphonates at the time of implant placement and during healing did not affect early implant success rates or crestal bone changes up to the time of stage-two surgery. In addition, the implant location and the duration of drug therapy at the time of placement were not significant factors in the success rate or bony changes. These conclusions must be viewed in the context of the limitations of the retrospective study design and should be confirmed in longer, more rigorously designed studies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23057037

Source DB:  PubMed          Journal:  Int J Oral Maxillofac Implants        ISSN: 0882-2786            Impact factor:   2.804


  7 in total

Review 1.  Bisphosphonate-related osteonecrosis of the jaw and dental implants.

Authors:  Ala Hassan A Qamheya; Sinem Yeniyol; Volkan Arisan
Journal:  J Istanb Univ Fac Dent       Date:  2016-01-12

2.  Dental implant treatment after healing of bisphosphonate-related osteonecrosis of the jaw (BRONJ) in the same region: a case report.

Authors:  Ji-Wan Kim; Jin Baik; Ju-Hong Jeon
Journal:  J Korean Assoc Oral Maxillofac Surg       Date:  2016-06-27

Review 3.  Indications and contraindications of dental implants in medically compromised patients: update.

Authors:  Rafael Gómez-de Diego; María del Rocío Mang-de la Rosa; María-Jesús Romero-Pérez; Antonio Cutando-Soriano; Antonio López-Valverde-Centeno
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2014-09-01

Review 4.  Bisphosphonate treatment and dental implants: A systematic review.

Authors:  N-R de-Freitas; L-B Lima; M-B de-Moura; C-C-F Veloso-Guedes; P-C Simamoto-Júnior; D de-Magalhães
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2016-09-01

Review 5.  Dental implants in patients treated with antiresorptive medication - a systematic literature review.

Authors:  Christian Walter; Bilal Al-Nawas; Tim Wolff; Eik Schiegnitz; Knut A Grötz
Journal:  Int J Implant Dent       Date:  2016-04-04

6.  Host inflammatory response and clinical parameters around implants in a rat model using systemic alendronate and zoledronate acid drug administrations.

Authors:  Kristian Kniha; Lothar Rink; Jana Wolf; Stephan Christian Möhlhenrich; Florian Peters; Marius Heitzer; Frank Hölzle; Ali Modabber
Journal:  Sci Rep       Date:  2022-03-15       Impact factor: 4.379

Review 7.  Effects of Systemic or Local Administration of Zoledronate on Implant Osseointegration: A Preclinical Meta-Analysis.

Authors:  Yao He; Wei Bao; Xiang-Dong Wu; Wei Huang; Hong Chen; Zhengyun Li
Journal:  Biomed Res Int       Date:  2019-09-22       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.